Figure 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors | Synapse
October 8, 2025
Figure 1 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
Key Points
Best change in target lesions from baseline indicates treatment impact on tumor size.
Patients with RCC showed marked responses, with some achieving stable disease.
The evaluation followed the Response Evaluation Criteria in Solid Tumours 1.1 framework.
The findings support further exploration of basroparib's role in treating advanced solid tumors.
Abstract
Best change (%) in target lesion from baseline. Note: “▲” marks patients with RCC; SD, stable disease in overall evaluation following Response Evaluation Criteria in Solid Tumours 1.1.